The results show significant upregulation of SOCS2 expression in AML and CML patients compared to healthy controls (Figure 2D), indicating that SOCS2 might play a role in those two myeloid malignancies. The gene discussed is SOCS2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.